LINAC

Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems' Versatility, Efficiency and Effectiveness

Retrieved on: 
Wednesday, May 17, 2023
Pancreatic cancer, Cyberknife, SBRT, Abstract, CE, Deep inspiration breath-hold, SRS, Radiation, Health care, DIBH, Prostate cancer, Metastasis, Cosmesis, Cancer, Quality of life, Lung cancer, Toxicity, MBA, Brain, Prostate, Sale, Movement, Synchrony, Radiation therapy, Motion, LINAC, Patient, Tomotherapy, Breast, Ultra, Accuracy and precision, Neoplasm, European Society for Medical Oncology, Congress, Health, Recurrence, Melphalan, Safety, Pharmaceutical industry, Medical imaging, Medical device, Dairy, Accuray

SUNNYVALE, Calif., May 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® and TomoTherapy® platforms, including the latest generation Radixact® System. More than 55 abstracts highlighting Accuray technologies were presented at the 2023 ESTRO annual congress held in Vienna, Austria, from May 12 to May 16, 2023, building on existing clinical evidence and supporting the systems' use to deliver (ultra) hypofractionated radiation treatments for the precise and personalized treatment of a wide range of cancers.

Key Points: 
  • During the meeting, Accuray hosted a symposium titled " Advances in Hypofractionation for Breast and Prostate Cancer " featuring clinical experts who discussed the most recent – and promising – clinical studies.
  • "The information sharing that takes place at meetings such as ESTRO is focused on the same critical goal – improving patient care.
  • Delivering ablative doses to target spinal metastases, ensuring good local control and low rates of toxicity while protecting critical organs5.
  • It is not CE marked and availability is subject to regulatory clearance or approval in some markets.

American Shared Hospital Services Reports First Quarter 2023 Financial Results

Retrieved on: 
Friday, May 12, 2023
Business development, Radiation, Interest, Proton therapy, AMS, Overalls, PT, Domestic international sales corporation, LINAC, Investment, SAN, Radiosurgery, Webcast, CFO, HVS Global Hospitality Services, Growth, Orlando Health, Three Months, H. Lee Moffitt Cancer Center & Research Institute, NYSE, Pharmaceutical industry, Lithium, Video game, Management, Medical imaging

SAN FRANCISCO, CA, May 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,903,000 for the first quarter of 2023, compared to $1,922,000 for the first quarter of 2022.
  • Net income attributable to American Shared Hospital Services in the first quarter of 2023 was $188,000, or $0.03 per diluted share, compared to net income of $269,000, or $0.04 per diluted share, for the first quarter of 2022.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,903,000 for the first quarter of 2023, compared to $1,922,000 for the first quarter of 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.

IntraOp Announces First Randomized Phase II Selection Trial of FLASH Versus Conventional Radiotherapy for Patients with Localized Carcinomas

Retrieved on: 
Friday, May 12, 2023
Oncology, Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Electron, University, Intraoperative electron radiation therapy, Therapeutic index, Toxicity, Medicine, SOC, Radiation therapy, Sale, CHUV, University of Lausanne, Teaching hospital, US, Radiation, LINAC, FLASH, Patient, Standard of care, NMSC, Safety, Lausanne University Hospital, Pharmaceutical industry, Medical imaging, Dermatology

It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).

Key Points: 
  • It marks the first time a randomized trial will compare FLASH radiotherapy* to conventional radiotherapy in treating nonmelanoma skin cancer (NMSC).
  • It is the second clinical human trial to use the IntraOp® Mobetron® electron-based linear accelerator (LINAC).
  • “This feels like a breakthrough moment in our collective study of the role and effectiveness of FLASH radiotherapy as compared to standard of care radiotherapy.
  • *Ultra-High Dose Rate (UHDR) functionality for FLASH Radiotherapy is for investigational use only and is not cleared for sale by the US FDA.

American Shared Hospital Services Reports Fourth Quarter and Year End 2022 Financial Results

Retrieved on: 
Friday, March 24, 2023
PBRT, Marketing, Proton therapy, Elekta, AMS, Overalls, GK, Cancer, ICON, PT, The Twelve Months, Lightning, EBITDA, LINAC, Patient, SAN, Radiosurgery, Webcast, CFO, Marine Hospital Service, Orlando Health, Three Months, MD Anderson Cancer Center, NYSE, Cryptocurrency, Pharmaceutical industry, Video game, Lithium

SAN FRANCISCO, CA, March 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the fourth quarter and twelve months ended December 31, 2022.

Key Points: 
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,161,000 for the fourth quarter of 2022, compared to $2,150,000 for the fourth quarter of 2021.
  • Net income attributable to American Shared Hospital Services was $1,328,000, or $0.21 per diluted share, compared to net income attributable to American Shared Hospital Services of $194,000, or $0.03 per diluted share, for 2021.
  • Net income attributable to American Shared Hospital Services in the fourth quarter 2022 was $246,000, or $0.04 per diluted share, compared to net income of $219,000, or $0.04 per diluted share, for the fourth quarter of 2021.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,161,000 for the fourth quarter of 2022, compared to $2,150,000 for the fourth quarter of 2021.

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

Retrieved on: 
Thursday, February 2, 2023
Radiology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Medical Devices, Health Technology, Radiation therapy, Toxicity, City, Biology, Reflection, Cancer, Combined, Radiation, LINAC, PET, Patient, Lung, Digestion, Food, Neoplasm, History, Movement, Map, Disease, X1, Multimedia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Radiopharmaceutical, Control, Classification, Pharmaceutical industry, Medical imaging

RefleXion Medical , a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX ™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers.

Key Points: 
  • RefleXion Medical , a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX ™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers.
  • The company will host a live-stream event featuring both its co-founder and CEO discussing the breakthrough significance of SCINTIX therapy for cancer treatment.
  • This expands the RefleXion® X1 into the only dual-treatment modality platform that can treat patients with indicated solid tumors of any stage.
  • RefleXion is hosting a brief live stream event from its headquarters in Hayward, Calif., about the SCINTIX therapy clearance.

IntraOp and Vanderbilt University Medical Center Announce First Patient Treated for Pancreatic Cancer Using Intra-Operative Radiation Therapy With Electrons

Retrieved on: 
Wednesday, January 18, 2023
Science, Research, Surgery, Oncology, General Health, Health, Medical Devices, Hospitals, Spinal cord, Vanderbilt University Medical Center, IORT, Pancreas, Center of excellence, LINAC, Pancreatic cancer, Duodenum, Vanderbilt, Intraoperative electron radiation therapy, Patient, Cancer, FACS, Liver, VUMC, Stomach, Education, Electron, Pharmaceutical industry, Medical imaging, MSCI, MD, MMHC

IntraOp Medical Corporation announced today that doctors at Vanderbilt University Medical Center (VUMC) treated a pancreatic cancer patient using IntraOp® Mobetron® Intra-Operative Radiation Therapy (IORT).

Key Points: 
  • IntraOp Medical Corporation announced today that doctors at Vanderbilt University Medical Center (VUMC) treated a pancreatic cancer patient using IntraOp® Mobetron® Intra-Operative Radiation Therapy (IORT).
  • The procedure marks the first time VUMC — the largest comprehensive research, teaching and patient care health system in the Mid-South region — has utilized IORT with electrons in treating a patient with pancreatic cancer.
  • “We are encouraged by the results of the IORT with electrons in treating localized pancreatic cancer,” said Dr. Kamran Idrees.
  • “We serve our patients by implementing the latest innovations at Vanderbilt to improve outcomes.”
    Pancreatic cancer remains one of the deadliest forms of cancer.

Medicaid Cancer Foundation Launches Health Fund in Response to Cancer Moonshot

Retrieved on: 
Monday, January 9, 2023
Disease, Radiation, World Health Organization, Caregiver, COVID-19, HIV, LINAC, Government, PEPFAR, Particle accelerator, Patient, Cancer, Survivor, Pharmaceutical industry, African

The Medical Director of Medicaid Cancer Foundation H.E Dr. Zainab Shinkafi Bagudu has expressed her dedication to supporting cancer treatment and care in Nigeria and beyond.

Key Points: 
  • Abuja, Nigeria--(Newsfile Corp. - January 9, 2023) - Medicaid Cancer Foundation announces the launch of the Medicaid Cancer Health Fund in the wake of President Joe Biden's reignition of the cancer moonshot in February 2022.
  • The Medicaid Cancer Health Fund will broaden access to cancer care services in Northern Nigeria by linking beneficiaries to discount/free cancer services through its existing network of partners and building a comprehensive cancer treatment centre in Abuja.
  • Medicaid Cancer Foundation is committed to leveraging local and global contacts to deliver a one-stop-shop for the full complement of cancer treatment services in Nigeria.
  • The roadmap announced at the White House Cancer Moonshot Summit in December 2022 opens the door for capital and human resource investment from the United States to accelerate access to quality cancer care services in Africa.

Australia HospeTrack Hospital Intelligence Report 2022: Upcoming Developments in Cancer Care Infrastructure to Drive Demand in Australia's Medical Device Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 23, 2022
Hospitals, Health, Oncology, Prevalence, ICU, Medical Research Future Fund, Government, PET/CT, DEXA, Bed, Molecular imaging, LINAC, Life expectancy, PET, Incubator, MRI, Cancer, SPECT, Medicare, Cath lab, Research, Nuclear medicine, Mental health, Diabetes, ORS, Conditional sentence, CT, Diagnosis, University, Incidence, Medical imaging, Health insurance, Ultrasound, Mammography, Dialysis

Upcoming developments in cancer care infrastructure to drive demand in Australian medical device industry.

Key Points: 
  • Upcoming developments in cancer care infrastructure to drive demand in Australian medical device industry.
  • As of 2021-22, Australia has 655 public healthcare facilities and 1,317 private facilities including imaging centers.
  • Australia has the highest number of cancer cases in the world, with an estimated 150,000 cases of cancer diagnosed each year.
  • According to this HospeTrack Hospital Intelligence for Australia, nuclear medicine and molecular imaging market is likely to present pockets of growth opportunities primarily related to the increasing prevalence of cancer.

Mevion Identifies Site for New Compact Proton Therapy System in Development

Retrieved on: 
Sunday, October 23, 2022
Research, Medical Devices, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Adoption, LinkedIn, Risk, Science, Proton therapy, LINAC, Patient, PBS, Multimedia, Varian Medical Systems, Cancer, Secondary malignant neoplasm, Stanford University Medical Center, Scan (company), CEO, Radiation, Medical imaging, Proton

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS).

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS).
  • Historically, the size, cost, and inherent complexity of proton technologies have limited the adoption of proton therapy.
  • Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy.

Mevion Introduces New MEVION S250-FIT Proton Therapy System

Retrieved on: 
Friday, October 21, 2022
Research, Medical Devices, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Proton, LinkedIn, Transform, Hospital, Science, FLASH, Integration, LINAC, Patient, Research, Entrepreneurship, Annual general meeting, Multimedia, Harvard Medical School, Partnership, Varian Medical Systems, Cancer, Technology, C. C. Wang, Proton therapy, MD, Scan (company), Massachusetts General Hospital, Doctor of Philosophy, Industry, CEO, IGRT, Central Waqf Council, FIT, ARC, Radiation, Exhibition, Intensity, Mass, Medical imaging

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System.
  • View the full release here: https://www.businesswire.com/news/home/20221021005026/en/
    The MEVION S250-FIT Proton Therapy System (Photo: Business Wire)
    Enabled by the worlds smallest self-shielded proton accelerator from Mevion, the MEVION S250-FIT will be the first and only full proton therapy system that can fit in an existing LINAC vault.
  • Mevion will officially debut the MEVION S250-FIT Proton Therapy System at ASTROs 64th Annual Meeting in San Antonio, TX.
  • *The MEVION S250-FIT Proton Therapy System, FLASH therapy, online adaptive therapy, and ARC therapy are not yet available for clinical use.